Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 1/2019

Open Access 01-01-2019 | Review

The prognostic value of tumour–stroma ratio in primary breast cancer with special attention to triple-negative tumours: a review

Authors: C. J. H. Kramer, K. M. H. Vangangelt, G. W. van Pelt, T. J. A. Dekker, R. A. E. M. Tollenaar, W. E. Mesker

Published in: Breast Cancer Research and Treatment | Issue 1/2019

Login to get access

Abstract

Purpose

There is a strong need to improve the prognostication of breast cancer patients in order to prevent over- and undertreatment, especially when considering adjuvant chemotherapy. Tumour stroma characteristics might be valuable in predicting disease progression.

Methods

Studies regarding the prognostic value of tumour–stroma ratio (TSR) in breast cancer are evaluated.

Results

A high stromal content is related to a relatively poor prognosis. The most pronounced prognostic effect of this parameter seems to be observed in the triple-negative breast cancer (TNBC) subtype.

Conclusions

TSR assessment might represent a simple, fast and reproducible prognostic factor at no extra costs, and could possibly be incorporated into routine pathological diagnostics. Despite these advantages, a robust clinical validation of this parameter has yet to be established in prospective studies.
Appendix
Available only for authorised users
Literature
1.
2.
Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K et al (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295(21):2492–2502PubMedCrossRef
3.
Cancer Genome Atlas N (2012) Comprehensive molecular portraits of human breast tumours. Nature 490(7418):61–70CrossRef
4.
Engels CC, Kiderlen M, Bastiaannet E, Mooyaart AL, van Vlierberghe R, Smit VT et al (2016) The clinical prognostic value of molecular intrinsic tumor subtypes in older breast cancer patients: a FOCUS study analysis. Mol Oncol 10(4):594–600PubMedCrossRef
5.
Perou CM (2011) Molecular stratification of triple-negative breast cancers. Oncologist 16(1):61–70PubMedCrossRef
6.
de Kruijf EM, Bastiaannet E, Ruberta F, de Craen AJ, Kuppen PJ, Smit VT et al (2014) Comparison of frequencies and prognostic effect of molecular subtypes between young and elderly breast cancer patients. Mol Oncol 8(5):1014–1025PubMedPubMedCentralCrossRef
7.
Cardoso F, van’t Veer LJ, Bogaerts J, Slaets L, Viale G, Delaloge S et al (2016) 70-gene signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med 375(8):717–729PubMedCrossRef
8.
Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M et al (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351(27):2817–2826CrossRefPubMed
9.
Krop I, Ismaila N, Andre F, Bast RC, Barlow W, Collyar DE et al (2017) Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology clinical practice guideline focused update. J Clin Oncol 35(24):2838–2847PubMedPubMedCentralCrossRef
10.
Mesker WE, Junggeburt JM, Szuhai K, de Heer P, Morreau H, Tanke HJ et al (2007) The carcinoma-stromal ratio of colon carcinoma is an independent factor for survival compared to lymph node status and tumor stage. Cell Oncol 29(5):387–398PubMedPubMedCentral
11.
Courrech Staal EF, Smit VT, van Velthuysen ML, Spitzer-Naaykens JM, Wouters MW, Mesker WE et al (2011) Reproducibility and validation of tumour stroma ratio scoring on oesophageal adenocarcinoma biopsies. Eur J Cancer 47(3):375–382PubMedCrossRef
12.
de Kruijf EM, van Nes JG, van de Velde CJ, Putter H, Smit VT, Liefers GJ et al (2011) Tumor–troma ratio in the primary tumor is a prognostic factor in early breast cancer patients, especially in triple-negative carcinoma patients. Breast Cancer Res Treat 125(3):687–696PubMedCrossRef
13.
Moorman AM, Vink R, Heijmans HJ, van der Palen J, Kouwenhoven EA (2012) The prognostic value of tumour–stroma ratio in triple-negative breast cancer. Eur J Surg Oncol 38(4):307–313PubMedCrossRef
14.
Dekker TJ, van de Velde CJ, van Pelt GW, Kroep JR, Julien JP, Smit VT et al (2013) Prognostic significance of the tumor–stroma ratio: validation study in node-negative premenopausal breast cancer patients from the EORTC perioperative chemotherapy (POP) trial (10854). Breast Cancer Res Treat 139(2):371–379PubMedCrossRef
15.
Gujam FJ, Edwards J, Mohammed ZM, Going JJ, McMillan DC (2014) The relationship between the tumour stroma percentage, clinicopathological characteristics and outcome in patients with operable ductal breast cancer. Br J Cancer 111(1):157–165PubMedPubMedCentralCrossRef
16.
Vangangelt KMH, van Pelt GW, Engels CC, Putter H, Liefers GJ, Smit V et al Prognostic value of tumor–stroma ratio combined with the immune status of tumors in invasive breast carcinoma. Breast Cancer Res Treat. 2017
17.
Roeke T, Sobral-Leite M, Dekker TJA, Wesseling J, Smit V, Tollenaar R et al (2017) The prognostic value of the tumour–stroma ratio in primary operable invasive cancer of the breast: a validation study. Breast Cancer Res Treat 166(2):435–445PubMedCrossRef
18.
West NP, Dattani M, McShane P, Hutchins G, Grabsch J, Mueller W et al (2010) The proportion of tumour cells is an independent predictor for survival in colorectal cancer patients. Br J Cancer 102(10):1519–1523PubMedPubMedCentralCrossRef
19.
Park JH, Richards CH, McMillan DC, Horgan PG, Roxburgh CS (2014) The relationship between tumour stroma percentage, the tumour microenvironment and survival in patients with primary operable colorectal cancer. Ann Oncol 25(3):644–651PubMedPubMedCentralCrossRef
20.
Vogelaar FJ, van Pelt GW, van Leeuwen AM, Willems JM, Tollenaar RA, Liefers GJ et al (2016) Are disseminated tumor cells in bone marrow and tumor–stroma ratio clinically applicable for patients undergoing surgical resection of primary colorectal cancer? The Leiden MRD study. Cell Oncol (Dordr) 39(6):537–544CrossRef
21.
Aurello P, Berardi G, Giulitti D, Palumbo A, Tierno SM, Nigri G et al (2017) Tumor–Stroma Ratio is an independent predictor for overall survival and disease free survival in gastric cancer patients. Surgeon 15(6):329–335PubMedCrossRef
22.
Huijbers A, Tollenaar RA, v Pelt GW, Zeestraten EC, Dutton S, McConkey CC et al (2013) The proportion of tumor–stroma as a strong prognosticator for stage II and III colon cancer patients: validation in the VICTOR trial. Ann Oncol 24(1):179–185PubMedCrossRef
23.
Wang Z, Liu H, Zhao R, Zhang H, Liu C, Song Y (2013) Tumor–stroma ratio is an independent prognostic factor of non-small cell lung cancer. Zhongguo Fei Ai Za Zhi 16(4):191–196PubMed
24.
Mesker WE, Liefers GJ, Junggeburt JM, van Pelt GW, Alberici P, Kuppen PJ et al (2009) Presence of a high amount of stroma and downregulation of SMAD4 predict for worse survival for stage I-II colon cancer patients. Cell Oncol 31(3):169–178PubMedPubMedCentral
25.
Wu J, Liang C, Chen M, Su W (2016) Association between tumor–stroma ratio and prognosis in solid tumor patients: a systematic review and meta-analysis. Oncotarget 7(42):68954–68965PubMedPubMedCentral
26.
Chen Y, Zhang L, Liu W, Liu X (2015) Prognostic significance of the tumor–stroma ratio in epithelial ovarian cancer. Biomed Res Int 2015:589301PubMedPubMedCentral
27.
Hansen TF, Kjaer-Frifeldt S, Lindebjerg J, Rafaelsen SR, Jensen LH, Jakobsen A et al (2018) Tumor–stroma ratio predicts recurrence in patients with colon cancer treated with neoadjuvant chemotherapy. Acta Oncol 57(4):528–533PubMedCrossRef
28.
Li H, Yuan SL, Han ZZ, Huang J, Cui L, Jiang CQ et al (2017) Prognostic significance of the tumor–stroma ratio in gallbladder cancer. Neoplasma 64(4):588–593PubMedCrossRef
29.
Liu J, Liu J, Li J, Chen Y, Guan X, Wu X et al (2014) Tumor–stroma ratio is an independent predictor for survival in early cervical carcinoma. Gynecol Oncol 132(1):81–86PubMedCrossRef
30.
Lv Z, Cai X, Weng X, Xiao H, Du C, Cheng J et al (2015) Tumor–stroma ratio is a prognostic factor for survival in hepatocellular carcinoma patients after liver resection or transplantation. Surgery 158(1):142–150PubMedCrossRef
31.
Niranjan KC, Sarathy NA (2018) Prognostic impact of tumor–stroma ratio in oral squamous cell carcinoma: a pilot study. Ann Diagn Pathol 35:56–61PubMedCrossRef
32.
Pongsuvareeyakul T, Khunamornpong S, Settakorn J, Sukpan K, Suprasert P, Intaraphet S et al (2015) Prognostic evaluation of tumor–stroma ratio in patients with early stage cervical adenocarcinoma treated by surgery. Asian Pac J Cancer Prev 16(10):4363–4368PubMedCrossRef
33.
Scheer R, Baidoshvili A, Zoidze S, Elferink MAG, Berkel AEM, Klaase JM et al (2017) Tumor–stroma ratio as prognostic factor for survival in rectal adenocarcinoma: a retrospective cohort study. World J Gastrointest Oncol 9(12):466–474PubMedPubMedCentralCrossRef
34.
Wang K, Ma W, Wang J, Yu L, Zhang X, Wang Z et al (2012) Tumor–stroma ratio is an independent predictor for survival in esophageal squamous cell carcinoma. J Thorac Oncol 7(9):1457–1461PubMedCrossRef
35.
Xi KX, Wen YS, Zhu CM, Yu XY, Qin RQ, Zhang XW et al (2017) Tumor–stroma ratio (TSR) in non-small cell lung cancer (NSCLC) patients after lung resection is a prognostic factor for survival. J Thorac Dis 9(10):4017–4026PubMedPubMedCentralCrossRef
36.
Zhang R, Song W, Wang K, Zou S (2017) Tumor–stroma ratio(TSR) as a potential novel predictor of prognosis in digestive system cancers: a meta-analysis. Clin Chim Acta 472:64–68PubMedCrossRef
37.
Zhang T, Xu J, Shen H, Dong W, Ni Y, Du J (2015) Tumor–stroma ratio is an independent predictor for survival in NSCLC. Int J Clin Exp Pathol 8(9):11348–11355PubMedPubMedCentral
38.
Zhang XL, Jiang C, Zhang ZX, Liu F, Zhang F, Cheng YF (2014) The tumor–stroma ratio is an independent predictor for survival in nasopharyngeal cancer. Oncol Res Treat 37(9):480–484PubMedCrossRef
39.
Mueller MM, Fusenig NE (2004) Friends or foes - bipolar effects of the tumour stroma in cancer. Nat Rev Cancer 4(11):839–849PubMedCrossRef
40.
Junttila MR, de Sauvage FJ (2013) Influence of tumour micro-environment heterogeneity on therapeutic response. Nature 501(7467):346–354PubMedCrossRef
41.
Hawinkels LJ, Paauwe M, Verspaget HW, Wiercinska E, van der Zon JM, van der Ploeg K et al (2014) Interaction with colon cancer cells hyperactivates TGF-beta signaling in cancer-associated fibroblasts. Oncogene 33(1):97–107PubMedCrossRef
42.
Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K et al (2000) Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2(10):737–744PubMedPubMedCentralCrossRef
43.
Levental KR, Yu H, Kass L, Lakins JN, Egeblad M, Erler JT et al (2009) Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 139(5):891–906PubMedPubMedCentralCrossRef
44.
Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, Zhao H et al (2008) Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 14(5):518–527PubMedCrossRef
45.
Farmer P, Bonnefoi H, Anderle P, Cameron D, Wirapati P, Becette V et al (2009) A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nat Med 15(1):68–74PubMedCrossRef
46.
Downey CL, Simpkins SA, White J, Holliday DL, Jones JL, Jordan LB et al (2014) The prognostic significance of tumour–stroma ratio in oestrogen receptor-positive breast cancer. Br J Cancer 110(7):1744–1747PubMedPubMedCentralCrossRef
47.
48.
Clahsen PC, van de Velde CJ, Julien JP, Floiras JL, Delozier T, Mignolet FY et al (1996) Improved local control and disease-free survival after perioperative chemotherapy for early-stage breast cancer. A European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group Study. J Clin Oncol 14(3):745–753PubMedCrossRef
49.
Robertson FM, Bondy M, Yang W, Yamauchi H, Wiggins S, Kamrudin S et al (2010) Inflammatory breast cancer: the disease, the biology, the treatment. CA Cancer J Clin 60(6):351–375PubMedCrossRef
50.
Acs G, Kiluk J, Loftus L, Laronga C (2013) Comparison of Oncotype DX and Mammostrat risk estimations and correlations with histologic tumor features in low-grade, estrogen receptor-positive invasive breast carcinomas. Mod Pathol 26(11):1451–1460PubMedCrossRef
51.
Mesker WE, Dekker TJ, de Kruijf EM, Engels CC, van Pelt GW, Smit VT et al (2015) Comment on: The prognostic significance of tumour–stroma ratio in oestrogen receptor-positive breast cancer. Br J Cancer 112(11):1832–1833PubMedCrossRef
52.
Downey CL, Simpkins SA, Holliday DL, Jones JL, Jordan LB, Kulka J et al (2015) Reponse to: comment on, ‘Tumour–stroma ratio (TSR) in oestrogen-positive breast cancer patients’. Br J Cancer 112(11):1833–1834PubMedCrossRef
53.
Dekker TJ, Balluff BD, Jones EA, Schone CD, Schmitt M, Aubele M et al (2014) Multicenter matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI MSI) identifies proteomic differences in breast-cancer-associated stroma. J Proteome Res 13(11):4730–4738PubMedCrossRef
54.
Witkiewicz AK, Dasgupta A, Sotgia F, Mercier I, Pestell RG, Sabel M et al (2009) An absence of stromal caveolin-1 expression predicts early tumor recurrence and poor clinical outcome in human breast cancers. Am J Pathol 174(6):2023–2034PubMedPubMedCentralCrossRef
55.
Paulsson J, Sjoblom T, Micke P, Ponten F, Landberg G, Heldin CH et al (2009) Prognostic significance of stromal platelet-derived growth factor beta-receptor expression in human breast cancer. Am J Pathol 175(1):334–341PubMedPubMedCentralCrossRef
56.
Ahn S, Cho J, Sung J, Lee JE, Nam SJ, Kim KM et al (2012) The prognostic significance of tumor-associated stroma in invasive breast carcinoma. Tumour Biol 33(5):1573–1580PubMedCrossRef
57.
Leon-Ferre RA, Polley MY, Liu H, Gilbert JA, Cafourek V, Hillman DW et al (2018) Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer. Breast Cancer Res Treat 167(1):89–99PubMedCrossRef
58.
Tomioka N, Azuma M, Ikarashi M, Yamamoto M, Sato M, Watanabe KI et al (2018) The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC). Breast Cancer 25(1):34–42PubMedCrossRef
Metadata
Title
The prognostic value of tumour–stroma ratio in primary breast cancer with special attention to triple-negative tumours: a review
Authors
C. J. H. Kramer
K. M. H. Vangangelt
G. W. van Pelt
T. J. A. Dekker
R. A. E. M. Tollenaar
W. E. Mesker
Publication date
01-01-2019
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 1/2019
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-018-4987-4

Other articles of this Issue 1/2019

Breast Cancer Research and Treatment 1/2019 Go to the issue

Letter to the Editor

Association between red and processed meat with breast cancer: Comment on “Red and processed meat intake and risk of breast cancer: a meta-analysis of prospective studies” by Guo et al.

Correction

Correction to: Genomic landscape of small cell carcinoma of the breast contrasted to small cell carcinoma of the lung

Letter to the Editor

Regular exercise might be associated with higher skeletal muscle volume, favorable prognostic factor in breast cancer patients

Epidemiology

The association of socioeconomic status with receipt of neoadjuvant chemotherapy

Clinical trial

Dietary intervention among breast cancer survivors increased adherence to a Mediterranean-style, anti-inflammatory dietary pattern: the Rx for Better Breast Health Randomized Controlled Trial

Clinical trial

COOLHAIR: a prospective randomized trial to investigate the efficacy and tolerability of scalp cooling in patients undergoing (neo)adjuvant chemotherapy for early breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits